The global hospital acquired infections (HAIs) therapeutic market is witnessing steady growth, driven by increasing awareness of healthcare-associated infections, rising hospitalization rates, and the growing need for effective treatments. Valued at USD 10.45 billion in 2020, the market is projected to expand at a compound annual growth rate (CAGR) of 2.3% during the forecast period....